In vitro and in vivo anticancer effects of destruxin B on human colorectal cancer.

中山醫學大學機構典藏 CSMUIR > 醫學科技學院 > 醫學檢驗暨生物技術學系暨碩士班 > 期刊論文 > Item 310902500/11800

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/11800

题名:	In vitro and in vivo anticancer effects of destruxin B on human colorectal cancer.
作者:	Lee, YP Wang, CW Liao, WC Yang, CR Yeh, CT Tsai, CH Yang, CC Tzeng, YM
贡献者:	中山醫學大學
日期:	2012
上传时间:	2015-07-29T08:20:55Z (UTC)
摘要:	AIM: The study of the anticancer effects of destruxin B (DB) is rare and its anticancer mechanism remains unknown. The aim of this study was to test the in vitro and in vivo anticancer effects of DB, on human HT-29 colorectal cancer (CRC). MATERIALS AND METHODS: DB was isolated and characterized by high pressure liquid chromatography, electrospray ionization mass spectrometry and (1)H-nuclear magnetic resonance spectroscopy. (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to assess the effects of DB on HT-29 cells in vitro. The anticancer effects of DB were investigated in a murine xenograft model of human colon cancer. RESULTS: A significant inhibition of cell viability was observed with DB treatment in time- and dose-dependent manners. DB administered subcutaneously daily at 0.6-15 mg/kg was proven to be safe and effective in inhibiting the growth of CRC cells. Expression of Bax, cleaved poly (ADP-ribose) polymerase and active caspase-3 were observed with DB treatment and the increase in tumor volumes of treated groups were significantly (p<0.05) lower than those of the mock-treated group. CONCLUSION: DB has potential as a new therapeutic agent against human CRC.
URI:	https://ir.csmu.edu.tw:8080/ir/handle/310902500/11800
關聯:	Anticancer Res. 2012 Jul;32(7):2735-45.
显示于类别:	[醫學檢驗暨生物技術學系暨碩士班] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html	期刊論文	0Kb	HTML	316	检视/开启

检视Licence

在CSMUIR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....